Sponsors › Novo Nordisk

Novo Nordisk

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Novo Nordisk, drawn from ClinicalTrials.gov and Drugs@FDA.

Novo Nordisk is a commercial sponsor with 192 trials in the incretin class on file here, across 5 molecules. The programme is split between 35 early-stage trials and 157 in phase 3 or later. 30 approved FDA submissions sit against this sponsor in Drugs@FDA. The next scheduled result is 2027-03-01.

Molecules

cagrilintide · exenatide · liraglutide · semaglutide · tirzepatide

Trials on file

192

Active trials

23

Results scheduled

15

Approved FDA submissions

30

Results due

FDA record

Trials on file

All 192 incretin trials recorded for this sponsor, active first.